Paul van Hagen
Plus aucun poste en cours
Profil
Paul van Hagen is former Chief Financial Officer of Xeltis AG, former Senior Director-Finance & Control at Prosensa Holding NV, former Senior Vice President-Finance for Kiadis Pharma NV and former Senior Manager at Ernst & Young Nederland LLP (Netherlands).
He received an undergraduate degree from the University of Groningen.
Anciens postes connus de Paul van Hagen
Sociétés | Poste | Fin |
---|---|---|
Ernst & Young Nederland LLP (Netherlands)
Ernst & Young Nederland LLP (Netherlands) Miscellaneous Commercial ServicesCommercial Services Ernst & Young Nederland LLP provides accounting services. It offers advisory, assurance, tax, growth market, transaction, and specialty services. The company was founded by Barend Moret in 1883 and is headquartered in Rotterdam, the Netherlands. | Corporate Officer/Principal | - |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Director of Finance/CFO | - |
KIADIS PHARMA N.V. | Director of Finance/CFO | - |
PROSENSA HOLDING NV | Director of Finance/CFO | - |
Formation de Paul van Hagen
University of Groningen | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 4 |
---|---|
Ernst & Young Nederland LLP (Netherlands)
Ernst & Young Nederland LLP (Netherlands) Miscellaneous Commercial ServicesCommercial Services Ernst & Young Nederland LLP provides accounting services. It offers advisory, assurance, tax, growth market, transaction, and specialty services. The company was founded by Barend Moret in 1883 and is headquartered in Rotterdam, the Netherlands. | Commercial Services |
Prosensa Holding NV
Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Health Technology |
Kiadis Pharma NV
Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |